The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloid malignancies.
O. Odenike
Honoraria - Celgene
Research Funding - TopoTarget
L. A. Godley
Research Funding - Celgene; Celgene
J. Madzo
No relevant relationships to disclose
T. Karrison
No relevant relationships to disclose
M. Green
No relevant relationships to disclose
A. S. Artz
No relevant relationships to disclose
R. J. Mattison
No relevant relationships to disclose
K. W. L. Yee
No relevant relationships to disclose
M. Bennett
No relevant relationships to disclose
N. Fulton
No relevant relationships to disclose
G. Koval
No relevant relationships to disclose
G. Malnassy
No relevant relationships to disclose
R. A. Larson
No relevant relationships to disclose
M. J. Ratain
No relevant relationships to disclose
W. Stock
No relevant relationships to disclose